Jennifer Lachey Keros Therapeutics, Inc. (KROS) insider trading activity

Jennifer Lachey is Chief Scientific Officer of Keros Therapeutics, Inc.. Currently has a direct ownership of 95,100 shares of KROS, which is worth approximately $5.15 Million. The most recent transaction as insider was on Jul 15, 2022, when has been sold 46,034 shares (Common Stock) at a price of $30.0 per share, resulting in proceeds of $1,381,020. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 95.1K

0% 3M change

0% 12M change

Total Value Held $5.15 Million

Jennifer Lachey Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 15 2022	SELL Open market or private sale	$1,381,020 $30.0 p/Share	46,034 Reduced 32.62%	95,100 Common Stock
Jul 15 2022	BUY Exercise of conversion of derivative security	$13,810 $0.3 p/Share	46,034 Added 24.6%	141,134 Common Stock
Jul 13 2022	SELL Open market or private sale	$57,480 $30.0 p/Share	1,916 Reduced 1.97%	95,100 Common Stock
Jul 13 2022	BUY Exercise of conversion of derivative security	$575 $0.3 p/Share	1,916 Added 2.01%	93,184 Common Stock
Jun 14 2022	BUY Exercise of conversion of derivative security	$2,820 $0.3 p/Share	9,400 Added 9.0%	95,100 Common Stock
May 11 2022	SELL Open market or private sale	$229,755 $43.35 p/Share	5,300 Reduced 5.82%	85,700 Common Stock
May 11 2022	BUY Exercise of conversion of derivative security	$1,590 $0.3 p/Share	5,300 Added 5.5%	91,000 Common Stock
Apr 11 2022	SELL Open market or private sale	$333,052 $62.84 p/Share	5,300 Reduced 5.82%	85,700 Common Stock
Apr 11 2022	BUY Exercise of conversion of derivative security	$1,590 $0.3 p/Share	5,300 Added 5.5%	91,000 Common Stock
Apr 04 2022	SELL Open market or private sale	$477,000 $60.0 p/Share	7,950 Reduced 8.49%	85,700 Common Stock
Apr 04 2022	BUY Exercise of conversion of derivative security	$2,385 $0.3 p/Share	7,950 Added 7.82%	93,650 Common Stock
Mar 11 2022	SELL Open market or private sale	$141,616 $53.44 p/Share	2,650 Reduced 3.0%	85,700 Common Stock
Mar 11 2022	BUY Exercise of conversion of derivative security	$795 $0.3 p/Share	2,650 Added 2.91%	88,350 Common Stock
Feb 11 2022	SELL Open market or private sale	$138,648 $52.32 p/Share	2,650 Reduced 3.0%	85,700 Common Stock
Feb 11 2022	BUY Exercise of conversion of derivative security	$795 $0.3 p/Share	2,650 Added 2.91%	88,350 Common Stock
Jan 11 2022	SELL Open market or private sale	$141,351 $53.34 p/Share	2,650 Reduced 3.0%	85,700 Common Stock
Jan 11 2022	BUY Exercise of conversion of derivative security	$795 $0.3 p/Share	2,650 Added 2.91%	88,350 Common Stock
Jan 05 2022	SELL Open market or private sale	$159,000 $60.0 p/Share	2,650 Reduced 3.0%	85,700 Common Stock
Jan 05 2022	BUY Exercise of conversion of derivative security	$795 $0.3 p/Share	2,650 Added 2.91%	88,350 Common Stock
Dec 15 2021	SELL Open market or private sale	$36,750 $50.0 p/Share	735 Reduced 0.85%	85,700 Common Stock
Dec 15 2021	BUY Exercise of conversion of derivative security	$221 $0.3 p/Share	735 Added 0.84%	86,435 Common Stock
Dec 13 2021	SELL Open market or private sale	$99,561 $51.99 p/Share	1,915 Reduced 2.19%	85,700 Common Stock
Dec 13 2021	BUY Exercise of conversion of derivative security	$575 $0.3 p/Share	1,915 Added 2.14%	87,615 Common Stock
Nov 11 2021	SELL Open market or private sale	$314,025 $59.25 p/Share	5,300 Reduced 5.82%	85,700 Common Stock
Nov 11 2021	BUY Exercise of conversion of derivative security	$1,590 $0.3 p/Share	5,300 Added 5.5%	91,000 Common Stock

Jennifer Lachey

Chief Scientific Officer

Lexington, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KROS shares.

Notify only if

Value

Insider Trading

Get notified when an Keros Therapeutics, Inc. insider buys or sells KROS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Keros Therapeutics, Inc.

Track Activities on KROS

Account